Oramed Pharmaceuticals Inc.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oramed Pharmaceuticals specializes in developing oral drug delivery systems for injectable therapies, focusing on diabetes treatment in Israel.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-23 17:53 |
Delisting Announcement
Option Agreement for the Repurchase of Warrants
|
English | 316.7 KB | |
| 2025-07-23 17:53 |
Foreign Filer Report
Option Agreement for the Repurchase of Warrants
|
English | 36.4 KB | |
| 2025-07-18 14:52 |
Proxy Solicitation & Information Statement
Other Report or Announcement
|
English | 1.4 MB | |
| 2025-07-18 14:52 |
Proxy Solicitation & Information Statement
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-07-18 14:51 |
Registration Form
Other Report or Announcement
|
English | 448.1 KB | |
| 2025-07-18 14:51 |
Registration Form
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-07-18 14:50 |
Annual / Quarterly Financial Statement
Other Report or Announcement
|
English | 359.9 KB | |
| 2025-07-18 14:50 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-06-10 11:06 |
Director's Dealing
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 574.4 KB | |
| 2025-06-10 11:06 |
Foreign Filer Report
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 36.2 KB | |
| 2025-05-22 08:30 |
Transaction in Own Shares
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 92.1 KB | |
| 2025-05-22 08:30 |
Foreign Filer Report
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 36.4 KB | |
| 2025-05-16 13:29 |
Quarterly Report
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 1.1 MB | |
| 2025-05-16 13:29 |
Foreign Filer Report
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 36.3 KB | |
| 2025-04-29 11:13 |
Share Issue/Capital Change
FORM 8-K-entered into purchase agreement of 14,110,121 of Alpha Tau’s ordinary …
|
English | 400.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |